HempStreet, India’s first research to retail venture in the ayurvedic cannabis sector, has launched
Sarpagandha Vati. Coming in the form of a tablet, Sarpagandha Vati helps treat Hypertension and
Insomnia due to its calmative properties. HempStreet’s dispensation works through a network of doctors
who can buy the product via HempStreet’s B2B channels. This medicine is safe and reliable for middle
and even old age people (39-70 years) who are at higher risk of side effects. The classical ayurvedic
formulation outperforms other drugs in the same therapeutic range when combined with more potent
herbs such as Vijaya (Cannabis Sativa) and Jatamansi (Nardostachys Jatamansi).
Each tablet of ‘Sarpagandha Vati’ contains Sarpagandha (262.20 mg), Khurasani Ajwain (52.44 mg),
Jatamansi (26.22 mg), Vijaya (26.22 mg) and Pipalimula (4.92 mg). This Ayurvedic medicine calms the
nervous system, aids in the maintenance of normal blood pressure, and maintains oxygen balance that
helps regulate blood pressure in hypertensive patients. Additionally, Sarpagandha Vati’s diuretic and
detoxifying properties benefit people with the following health and lifestyle issues:
● Help manage Epilepsy and Delirium
● Help combat anxiety disorder
● Help curb the desire for Alcohol
● Induce natural sleep to defy Insomnia
While conventional medications have serious health consequences, Ayurveda offers a natural, holistic,
safe, and effective alternative to alleviate the condition of Hypertension. Sarpagandha Vati aims at
providing a reliable and safe ayurvedic solution to hypertensive patients by regulating their blood
pressure.
About HempStreet
HempStreet is India’s first research to retail medicinal cannabis venture, working towards amalgamating
the age-old science of Ayurveda with modern cannabis research to develop sustainable and economical
solutions for mass ailments. All of this while ensuring end-to-end blockchain technology-based supply
chain tracking to minimize any chance of abuse. HempStreet’s dispensation network of more than 11000
partner clinics across 26 states of India is a testament to the efficacy of the formulations and the trust of
medical practitioners in the brand. The company is also India’s first medicinal cannabis venture to have
been awarded the prestigious Biotechnology Ignition Grant (BIG) of BIRAC. Recently HempStreet
partnered with Gynica, an R&D company based out of Israel focused on changing the culture of
gynecological treatment through clinically proven, cannabinoid-based solutions.
